Answers are grounded in this paper and cite their sources.
Background: The Envisia Genomic Classifier (EGC) is a clinically validated molecular diagnostic test identifying usual interstitial pneumonia (UIP), increasing the diagnostic confidence for idiopathic pulmonary fibrosis in patients with interstitial lung disease (ILD). Research Question: What is the association of the EGC and lung cryobiopsy on clinical management decisions in patients with fibrotic ILD? Study Design and Methods: Retrospective analysis of patients at multimedical centers. We assessed the change in management strategy after EGC and cryobiopsy. We evaluated the association between genomic UIP classification and disease progression using the American Thoracic Society definition of progressive pulmonary fibrosis (method 1), or combined end point of death from any cause, lung transplant, or ≥ 10% relative decline in FVC (method 2). Interpretation: This study suggests that combined EGC and cryobiopsy are associated with change in therapeutic strategy in patients with undiagnosed ILD. The EGC might serve as a predictor for disease progression in patients not treated with antifibrotics.
No takes yet. Share an insight, caveat, or question.
Kheir et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: